Finding the Endless Frontier
Lessons from the Life Sciences Innovation System for Technology Policy
Bibliographic Data
| ID | 8246750 |
|---|---|
| Authors | Iain M Cockburn, Iain Cockburn (0000-0003-2034-0187, Quest University Canada, corresponding author), Scott Stern (Massachusetts Institute of Technology) |
| Year | 2010 |
| Volume | 5 |
| Issue | 1 |
| Publication date | 2010-01-16 |
| Peer Reviewed | Yes |
| Open Access | No |
| Type | ARTICLE |
| Venue | Capitalism and Society (JOURNAL) |
| Journal identifiers | ISSN: 1932-0213 • E-ISSN: 2194-6140 |
| Publisher | Walter de Gruyter GmbH (PUBLISHER • DE) |
| DOI | 10.2202/1932-0213.1071 |
| OpenAlex | W2054801437 |
| Language | EN |
| Citations received | 4 |
This paper considers the drivers of the structure and evolution of the life sciences innovation system, a remarkable success story for public support of science. The growth and performance of this system reflect the interaction between abundant scientific and technological opportunity, a reasonably effective and adaptive institutional and property rights framework, and a reservoir of unmet demand for therapies and technologies that significantly enhance human health care. Examining the evolution and dynamism of the life sciences innovation system, we emphasize three central foundations: a long-term and relatively stable commitment of financial and human resources by both the public sector and for-profit organizations, market and non-market institutions that encourage competition on the basis of innovation across multiple dimensions, and the promise of significant financial rewards for private sector innovators leveraging publicly funded scientific discoveries.Comments on this paper can be found at: http://ssrn.com/abstract=2208680
Business · Competition (biology · Dynamism · Economic growth · Economics · Economy · Frontier · Industrial organization · Innovation system · Intellectual property · Neoclassical economics · Political science · Private sector · Profit (economics · Public sector · Biotechnology and Related Fields · Innovation Policy and RD · Pharmaceutical Economics and Policy
| Unique citing works | 4 |
|---|---|
| Citations per year | 0,25 |
| Citation span | 2010 - 2022 (13) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 4 |